|
Developed by 
|
Supported by 
|
Ultra-Long Acting Buprenorphine Prodrug (AM-510)
Developer(s)
|
University of Nebraska Medical Center Originator
https://www.unmc.edu/
United States of America Nebraska Medical Center began with UNMC, founded in 1869 and chartered in 1881 as Omaha Medical College. It joined the University of Nebraska in 1902. The modern center formed in 1997 when University Hospital merged with Clarkson Hospital. Today, UNMC/Nebraska Medicine is known for care, research, and drug discovery through pharmacy, nanomedicine, cancer, and drug design programs. |
|
Exavir Therapeutics Originator
https://www.exavirtherapeutics.com/
United States of America Exavir Therapeutics, Inc. is a San Francisco-based biotechnology company co-founded by Howard Gendelman, Benson Edagwa, and Alborz Yazdi. Originating from UNMC-linked HIV nanomedicine research, it develops ultra-long-acting antivirals, including prodrug formulations for HIV PrEP and treatment. Its pipeline includes VH-310, XV-122, and XV-207, with ViiV Healthcare partnering on VH-310. |
Drug structure
Structure of Buprenorphine analog/prodrug series of 5α,6β,14β,18R)-17-(cyclopropylmethyl)-18-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol
https://www.natap.org/2026/CROI/croi_189.htm
Sequential Steps of Ultra long acting buprenorphine PK profile
https://www.natap.org/2026/CROI/croi_189.htm
Drug information
Associated long-acting platforms
Polymer-based particles
Administration route
Subcutaneous, Intramuscular
Therapeutic area(s)
Use case(s)
Not provided
Use of drug
Ease of administration
Frequency of administration
User acceptance
Dosage
Available dose and strength
AM-510 - 45mg/kg IM; 90 mg/kg IM & SC preclinical doses
Maximum dose
90 mg/kg IM
Recommended dosing regimen
1) 45 mg/kg SC STAT 2) 45 mg/kg IM STAT 3) 90 mg/kg IM STAT
Additional comments
Not provided
Dosage link(s)
Not provided